Skip to main content

Phase 3 Readout

ABBV: Phase 3 Topline: An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With

June 19, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
June 19, 2026
Company
AbbVie Inc. (ABBV)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout

Phase 3 Topline: An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With

ABBV overview →
Indication
Ocular Hypertension; Open-Angle Glaucoma

Other upcoming events for ABBV

Phase 2 StartPhase 2 Start: A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinatio
Phase 2 StartPhase 2 Start: A Phase 2 Open-Label Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotu
Phase 3 ReadoutPhase 3 Topline: Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy an